Ricardo Pillai
Sun, April 26, 2026 astatine 5:09 PM CDT 3 min read
Is VEEV a bully banal to buy? We came crossed a bullish thesis on Veeva Systems Inc. connected Danny’s Substack by Danny Green. In this article, we volition summarize the bulls’ thesis connected VEEV. Veeva Systems Inc.'s stock was trading astatine $167.95 arsenic of April 17th. VEEV’s trailing and guardant P/E were 30.87 and 18.94, respectively according to Yahoo Finance.
Wichy/Shutterstock.com
Veeva Systems Inc. provides cloud-based bundle for the beingness sciences manufacture successful North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. VEEV operates astatine the halfway of a durable, non-cyclical integer translation wrong the planetary beingness sciences industry, positioning itself arsenic the halfway operating strategy for captious workflows spanning objective development, regulatory compliance, and commercialized operations.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The institution benefits from beardown secular tailwinds, including rising pharmaceutical R&D spending driven by aging populations, expanding unit to accelerate cause improvement timelines, and accelerated adoption of AI-driven solutions, each of which reenforce request for Veeva’s integrated unreality platform.
Despite a impermanent slowdown successful FY2024, Veeva has re-accelerated growth, delivering 16.2% gross enlargement successful FY2025 with improving gross prime arsenic subscription services present comprise astir 84% of full revenue. The SaaS exemplary continues to thrust meaningful operating leverage, with important borderline enlargement expected arsenic the institution transitions distant from Salesforce, eliminating astir $80 cardinal successful yearly royalty payments by 2030.
Veeva’s ascendant manufacture position, including astir 80% marketplace stock successful beingness sciences CRM and heavy penetration crossed apical pharmaceutical companies, creates precocious switching costs and a almighty competitory moat reinforced by regulatory complexity. Financially, the institution maintains a fortress equilibrium expanse with implicit $6.5 cardinal successful nett currency and beardown escaped currency travel generation, enabling continued concern and strategical flexibility.
While near-term concerns astir CRM contention and lawsuit renewals person pressured valuation, this appears mostly sentiment-driven alternatively than fundamental. With aggregate catalysts, including CRM migration success, AI monetization, and continued R&D level expansion, Veeva presents a compelling semipermanent accidental with favorable risk-reward skew and imaginable for sustained compounding growth.

1 hour ago
1





English (CA) ·
English (US) ·
Spanish (MX) ·